Search
Philadelphia, PA Paid Clinical Trials
A listing of 1881 clinical trials in Philadelphia, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
457 - 468 of 1881
There are currently 1881 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
Recruiting
Einstein Medical Center in Philadelphia serves a diverse group of the patient population. The majority of patients have a diverse cultural background, low literacy, and poor social-economic status. Medication adherence for chronic medical problems is in a range of 40-70%. Medication adherence among patients on oral anti-cancer therapy is not studied in detail. The main objective is to study medication adherence to oral anticancer agents in patients with low literacy and poor socio-economic statu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Albert Einstein Healthcare Network, Philadelphia, Pennsylvania
Conditions: Cancer
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Recruiting
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Solid Tumor, Rhabdomyosarcoma
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Recruiting
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
06/18/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Non-Small Cell Lung Cancer
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Recruiting
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Advanced Colon Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Salivary Gland Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Salivary Gland Carcinoma, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Salivary Gland Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
SPEARHEAD-3 Pediatric Study
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philedephia, Philadelphia, Pennsylvania
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Osteosarcoma, Neuroblastoma (NBL)
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Autism Spectrum Disorder
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.
Recruiting
The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE® in male patients 2 years of age or older with Duchenne's Muscular Dystrophy for long term safety and quality of life.
Gender:
MALE
Ages:
2 years and above
Trial Updated:
06/18/2025
Locations: Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania
Conditions: Duchenne Muscular Dystrophy
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Recruiting
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Conditions: Candidiasis, Invasive, Candidemia
Facilitating Access to Specialty Treatment
Recruiting
The goal of this hybrid implementation-effectiveness study is to evaluate the effectiveness (hastened recovery times) and feasibility (fidelity in connecting to concussion specialty care) of a novel mobile health intervention, designed to reduce disparities in access to specialty care through the use of remote patient monitoring (RPM) to facilitate care hand-off from the emergency department (ED) to concussion specialty care. Participants will report their symptoms and activity once daily throug... Read More
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
06/17/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Mild Traumatic Brain Injury, Concussion, Mild, Concussion, Severe, Concussion, Intermediate
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Heart Failure, Systemic Inflammation
457 - 468 of 1881